Relief Therapeutics presents interim findings of PKU GOLIKE® trial at SSIEM 2024, showing potential for lowering Phe levels in children with PKU.

Relief Therapeutics, a Swiss biopharmaceutical firm, will present interim findings from its clinical trial of PKU GOLIKE® at the SSIEM 2024 Annual Symposium. The study, conducted at Birmingham Children's Hospital, assessed PKU GOLIKE's effectiveness compared to standard amino acid substitutes in managing overnight phenylalanine (Phe) levels in children with phenylketonuria (PKU). Preliminary results show PKU GOLIKE may lower Phe and raise tyrosine levels. Final results will follow further data analysis.

September 02, 2024
4 Articles